The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us


AML causes changes to blood cell counts. The aim of any treatment for AML is to help control the abnormal leukemia cells and restore a balance of healthy blood cells.

AML cannot be defined as a single disease, your symptoms will vary depending on the type of AML you have. Therefore, a variety of therapies are used for different types of AML and result in different outcomes.

Know AML has put together the animation below summarizing the treatment options available to people with AML.

What is chemotherapy?

The standard treatment for most people with AML is chemotherapy. Chemotherapy involves using anticancer drugs to destroy abnormal leukemia cells, which hopefully leads to remission. Chemotherapy is usually given in two main phases: (1) induction and (2) consolidation, which are explained in more detail below.

Induction phase

Induction chemotherapy is used in the first phase of treatment, it aims to kill abnormal leukemia cells and stop them from multiplying in the blood and bone marrow. The most common induction chemotherapies include cytarabine and an anthracycline drug (daunorubicin, idarubicin, or mitoxantrone); these are mostly offered to people younger than 60 years old, or people who are aged over 60 years and considered ‘fit’. Another treatment used for induction chemotherapy is the combination of daunorubicin and cytarabine (CPX-351), which is approved in the United States and Europe to treat people with specific types of AML, including therapy-related AML and AML with myelodysplasia-related changes. Induction chemotherapy can sometimes be administered with other drugs that target specific changes on or in leukemia cells, known as targeted therapies.

Consolidation phase

Consolidation chemotherapy aims to kill and remove abnormal leukemia cells that may remain after induction chemotherapy, but that cannot be detected. This reduces the risk of the leukemia cells multiplying and the subsequent return of AML. The consolidation phase involves further treatment with chemotherapy, often with the same drugs that were used in the induction phase.

Stem cell transplant

Often, chemotherapy and targeted therapies are followed by a stem cell transplant. This is because some AML therapies will remove a proportion of normal, healthy blood cells along with the leukemia cells. A stem cell transplant is used to introduce stem cells that go on to produce healthy blood cells.

What treatments are available for people who are ineligible for intensive chemotherapy?

Standard intensive chemotherapy may not be appropriate for you because of additional factors, such as age or other health conditions. However, there are still several treatment options available, including glasdegib with LDAC (low-dose cytarabine), low-intensity HMAs (hypomethylating agents) such as azacitidine and decitabine, and supportive care. Venetoclax can be used in combination with LDAC or an HMA for people who are ineligible for intensive chemotherapy.

How is relapsed or refractory AML treated?

Currently, treatment approaches for relapsed or refractory AML depend on a risk–benefit assessment, which analyzes the likely benefit of further therapy as well as the potential risks associated with it. The treatment decision is based on a number of factors, including age, length of remission, genetics, any previous stem cell transplant, general health status, and the patient’s wishes.

If considered eligible for intensive chemotherapy, treatment options include the following:

  • IDAC (intermediate-dose cytarabine) with filgrastim and either cladribine, fludarabine, or clofarabine
  • IDAC with etoposide with or without filgrastim
  • CLAG-M (cladribine, cytarabine, and mitoxantrone)
  • FLAG-IDA (fludarabine, cytarabine, filgrastim, and idarubicin)
  • Clofarabine, cytarabine, filgrastim, and idarubicin
  • HDAC (high-dose cytarabine) with or without idarubicin, daunorubicin, or mitoxantrone (for people who have not previously received this combination)

If intensive chemotherapy is not considered appropriate, the following treatment options are recommended:

  • HMAs (11-azacitidine or decitabine)
  • LDAC
  • Venetoclax in combination with an HMA or LDAC

Enrollment into a clinical trial may also be an option for people with relapsed or refractory AML.

What is maintenance therapy?

Maintenance therapy refers to lower intensity treatments that may be offered to you following an intensive treatment course or if you are unable to complete intensive treatment. The aim of maintenance therapy is to lower the risk of relapse and prolong survival, while minimizing side effects.

What are the advances in formulations of chemotherapy?

When talking about medicines, a formulation refers to how the different components are combined to make a product that can be given easily. Advances in chemotherapy for AML include attempts to make the treatment safer, more effective, or more convenient. With this in mind, improvements to traditional chemotherapy have been developed, such as:

  • CC-486: A formulation of azacitidine that can be taken orally as a maintenance therapy.
  • CPX-351: A formulation of combined daunorubicin and cytarabine that is more easily absorbed by the body.

What is targeted therapy?

In recent years, a number of new drugs have been developed to target specific markers found in or on leukemia cells. These advances have resulted in targeted drugs, which work differently to standard chemotherapy and can be useful if particular abnormalities have been identified. Generally, targeted therapies have higher specificity for leukemia cells and aim to minimize side effects. Some approved targeted treatments for different types of AML are shown below.

FLT3 inhibitors

Approximately 30% of people with AML have abnormal changes in a gene called FLT3. These genetic changes give rise to different forms of the FLT3 protein, which can lead to the growth of leukemia cells.

Midostaurin: A drug that targets the abnormal FLT3 protein and blocks its function. Midostaurin can be used with standard chemotherapy to treat people who have abnormal changes in the FLT3 gene.

Gilteritinib: A drug that binds to the FLT3 protein and blocks its function. Gilteritinib can be used to treat people who have abnormal changes in the FLT3 gene.

IDH inhibitors

In some people with AML, abnormal changes are detected in the IDH1 or IHD2 genes, which interfere with normal cell processes.

Ivosidenib: A drug that blocks the function of the IDH1 protein in leukemia cells. Ivosidenib can be used to treat people who have abnormal changes in the IDH1 gene.

Enasidenib: A drug that blocks the function of the IDH2 protein in leukemia cells. Enasidenib can be used to treat people with abnormal changes in the IDH2 gene.

BCL-2 inhibitor

BCL‑2 is a protein found inside cells that helps leukemia cells to survive.

Venetoclax: A drug that blocks the BCL‑2 protein, resulting in increased leukemia cell death. Venetoclax can be used to treat people who are aged 75 years and older or those who have other medical conditions that prevent the use of standard chemotherapy.

Hedgehog pathway inhibitor

In a cell, the ‘hedgehog pathway’ is a finely tuned network of signaling molecules that are important in early-life development. In AML, disturbances in this pathway can give rise to cells that are resistant to certain treatments, helping leukemia cells survive.

Glasdegib: A drug that blocks the hedgehog pathway. Glasdegib can be used to treat people who are aged 75 years and older or who have other medical conditions that prevent the use of standard chemotherapy.

Antibody–drug conjugate

Antibody–drug conjugates contain an antibody (a synthetic immune protein that recognizes a specific target on leukemia cells) and an anticancer drug. The antibody is used to guide the drug to the leukemia cells, where it can destroy them.

Gemtuzumab ozogamicin: A drug made up of an antibody that specifically recognizes CD33 (a protein found on leukemia cells) and a chemotherapy drug.

What are clinical trials?

Clinical trials are medical studies involving people and are a key step towards optimizing treatments for different diseases. A clinical trial may be designed with the aim of improving current therapies or to investigate how safe and effective a new treatment is. There are various ongoing clinical trials investigating treatment options for AML.

A patient with AML may not respond to the therapies that are currently approved, and certain types of AML have little to no treatment options available. Therefore, taking part in a clinical trial may be the best option for some people and could provide the opportunity for effective disease treatment/management.

What treatment side effects may be expected?

Treatments for any medical condition can cause side effects. The side effects you may experience can vary depending on the treatment, i.e., chemotherapy/targeted therapy, and your overall health. For most people, side effects are temporary and will go away after treatment has finished or following changes to the treatment regimen, such as altered dosing.

Common side effects of treatment for AML include tiredness, increased risk of infection (impaired immune system), nausea, vomiting, hair loss, rashes, and low levels of red blood cells (anemia). Your leukemia specialist should advise you of the common side effects associated with any treatment you may have.

If you have any questions or concerns regarding treatment options, clinical trials, or side effects, reach out to your leukemia specialist.

In this section

What is AML?Causes & symptomsDiagnosisTypesTreatmentPrognosisRemissionRelapseCOVID-19Caregivers

Latest story

Hear from Dorcas about her experience of caring for someone with acute myeloid leukemia.

Asset 1

Sign up to the newsletter


Share this page